|Articles|March 25, 2019

Reducing Antibiotic Use Cuts Hospital-Onset C Diff Infections

Author(s)Jonna Lorenz

The study found that that acute care hospitals with a 20% reduction in fluoroquinolone or third and fourth generation cephalosporins had a “corresponding decrease” in hospital-onset C diff.

Decreased use of antibiotics is associated with reductions in hospital-onset Clostridium difficile (C diff) infection, according to a new study released by the US Centers for Disease Control and Prevention (CDC).

"The effect of antibiotics on increasing risk for [C diff] in patients has been well documented, but what this study adds is that antibiotic use on the population level (within a hospital) is associated with hospital rates of [C diff]. Specifically, hospitals with higher rates of total inpatient antibiotic use were found to have higher rates of [hospital-onset C diff]," Sophia Kazakova, MD, MPH, PhD, from the Division of Healthcare Quality Promotion at the National Center for Emerging and Zoonotic Infectious Diseases at the CDC, and a corresponding author of the study, told Contagion®.

The study, which looked at data from more than 500 acute care hospitals in the United States between 2006 and 2012, also found that the specific antibiotic classes—third- and fourth-generation cephalosporins and carbapenems—were associated with higher rates of hospital-onset C diff. It was the largest ecological investigation of the association to date.

Those acute care hospitals that saw significant decreases in antibiotic use also saw significant reductions in hospital-onset C diff.

"It was surprising to find how strongly the levels of antibiotic use and [hospital-onset C diff] correlated and represented almost a 'dose-response'-like relationship, where 20% or larger decrease in total antibiotic use corresponded with 22% decrease in [hospital-onset C diff] and 30% or larger decrease corresponded with 33% decrease in [hospital-onset C diff]," Dr. Kazakova told Contagion®.

Although very few acute care hospitals saw such large reductions in antibiotic use, Dr. Kazakova said that "for the hospitals with high levels of antibiotic consumption, this can be an inspirational finding.”

Dr. Kazakova also said that between 20% and 50% of all antibiotics used in hospitals are unnecessary or inappropriate.

The CDC established "core elements" of antibiotic stewardship programs, which have been incorporated in hospital certification programs, leading to an increase in such programs, with 75% of hospitals reporting that they had antibiotic stewardship programs in 2017, up from 40% in 2014. More research is needed to determine how antibiotic use is changing at those hospitals.

"Antibiotics can be life-saving for hospitalized patients, but they can also cause harm—not only to the treated individual, but also to other patients in that hospital," Dr. Kazakova said in the interview. "For instance, if a patient who is carrying [C diff] receives antibiotics, that patient may become more contagious and shed more [C diff] into the environment leading to transmission to other patients. Better use of antibiotics reduces risk of [C diff] infections for every hospitalized patient."

The study found moderate association with fluoroquinolone, and recommended targeting antibiotic stewardship programs to high-risk antibiotic classes as an alternative to targeting total antibiotic use. Other studies have suggested using penicillin-based antibiotics instead of flouroquinolones and cephalosporins, and more research is needed to determine the results of such efforts and their effect on C diff rates.

Safety concerns have led regulatory agencies to issue warnings about the use of fluoroquinolone antibiotics. Last year, the safety committee of the European Medicines Agency (EMA) recommended restricting the use of fluoroquinolone and quinolone antibiotics. The US Food and Drug Administration and Health Canada also have issues warnings.

Antimicrobial stewardship programs were supported by a study that found that de-escalation within 48 hours of broad-spectrum antibiotics reduced the incidence of C diff infection.


Related to this article

Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Drawing Borders Around a Borderless Specialty
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.